126 related articles for article (PubMed ID: 28661257)
1. Recreational 3,4-methylenedioxymethamphetamine or 'ecstasy': Current perspective and future research prospects.
Parrott AC; Downey LA; Roberts CA; Montgomery C; Bruno R; Fox HC
J Psychopharmacol; 2017 Aug; 31(8):959-966. PubMed ID: 28661257
[TBL] [Abstract][Full Text] [Related]
2. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users.
Parrott AC
Neurosci Biobehav Rev; 2013 Sep; 37(8):1466-84. PubMed ID: 23660456
[TBL] [Abstract][Full Text] [Related]
3. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.
Parrott AC
Hum Psychopharmacol; 2013 Jul; 28(4):289-307. PubMed ID: 23881877
[TBL] [Abstract][Full Text] [Related]
4. Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational 'ecstasy'.
Parrott AC
Behav Pharmacol; 2016 Dec; 27(8):649-658. PubMed ID: 27681116
[TBL] [Abstract][Full Text] [Related]
5. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.
Parrott AC; Buchanan T; Scholey AB; Heffernan T; Ling J; Rodgers J
Hum Psychopharmacol; 2002 Aug; 17(6):309-12. PubMed ID: 12404677
[TBL] [Abstract][Full Text] [Related]
6. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits.
Parrott AC; Lees A; Garnham NJ; Jones M; Wesnes K
J Psychopharmacol; 1998; 12(1):79-83. PubMed ID: 9584971
[TBL] [Abstract][Full Text] [Related]
7. Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users.
Parrott AC
Neuropsychobiology; 2009; 60(3-4):148-58. PubMed ID: 19893332
[TBL] [Abstract][Full Text] [Related]
8. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.
Parrott AC; Milani RM; Parmar R; Turner JD
Psychopharmacology (Berl); 2001 Dec; 159(1):77-82. PubMed ID: 11797073
[TBL] [Abstract][Full Text] [Related]
9. Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms?
Guillot C
J Psychoactive Drugs; 2007 Mar; 39(1):31-9. PubMed ID: 17523583
[TBL] [Abstract][Full Text] [Related]
10. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
11. MDMA, cortisol, and heightened stress in recreational ecstasy users.
Parrott AC; Montgomery C; Wetherell MA; Downey LA; Stough C; Scholey AB
Behav Pharmacol; 2014 Sep; 25(5-6):458-72. PubMed ID: 25014666
[TBL] [Abstract][Full Text] [Related]
12. Everyday memory deficits in ecstasy-polydrug users.
Montgomery C; Fisk JE
J Psychopharmacol; 2007 Sep; 21(7):709-17. PubMed ID: 17606476
[TBL] [Abstract][Full Text] [Related]
13. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
14. MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy.
Parrott AC; Moore DG; Turner JJ; Goodwin J; Min MO; Singer LT
Hum Psychopharmacol; 2014 Jan; 29(1):1-7. PubMed ID: 24424703
[TBL] [Abstract][Full Text] [Related]
15. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study.
Schilt T; de Win MM; Koeter M; Jager G; Korf DJ; van den Brink W; Schmand B
Arch Gen Psychiatry; 2007 Jun; 64(6):728-36. PubMed ID: 17548754
[TBL] [Abstract][Full Text] [Related]
16. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.
Parrott AC; Milani RM; Gouzoulis-Mayfrank E; Daumann J
J Neural Transm (Vienna); 2007; 114(8):959-68. PubMed ID: 17520319
[TBL] [Abstract][Full Text] [Related]
17. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).
Parrott AC
Hum Psychopharmacol; 2014 Mar; 29(2):109-19. PubMed ID: 24590542
[TBL] [Abstract][Full Text] [Related]
18. Discrete memory impairments in largely pure chronic users of MDMA.
Wunderli MD; Vonmoos M; Fürst M; Schädelin K; Kraemer T; Baumgartner MR; Seifritz E; Quednow BB
Eur Neuropsychopharmacol; 2017 Oct; 27(10):987-999. PubMed ID: 28866005
[TBL] [Abstract][Full Text] [Related]
19. Why all stimulant drugs are damaging to recreational users: an empirical overview and psychobiological explanation.
Parrott AC
Hum Psychopharmacol; 2015 Jul; 30(4):213-24. PubMed ID: 26216554
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
Gouzoulis-Mayfrank E; Daumann J
Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
